Diseases / Hypercholesterolemia
Hypercholesterolemia
DiseaseHypercholesterolemia is a lipid disorder characterized by elevated cholesterol levels, especially LDL cholesterol, in the blood. Persistent elevation contributes to atherosclerosis and increased risk of coronary heart disease and stroke. It can be primary (genetic) or secondary to lifestyle and other medical factors.
- Trials
- 1127
- Recruiting
- 49
- Completed
- 860
- With results
- 273
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | 1 | — | — | 6 | — | — | — | — | 7 |
| Phase 1 | 4 | — | 1 | — | 77 | 6 | 2 | — | 4 | 94 |
| Phase 1/2 | — | — | — | — | 8 | 1 | — | — | 1 | 10 |
| Phase 2 | 4 | 4 | — | — | 107 | 5 | 2 | — | 2 | 124 |
| Phase 2/3 | 1 | — | — | — | 7 | — | — | — | 1 | 9 |
| Phase 3 | 6 | 3 | 2 | 5 | 222 | 22 | 2 | — | 3 | 265 |
| Phase 4 | 5 | 2 | — | 2 | 109 | 9 | 3 | — | 17 | 147 |
| Not applicable | 19 | 6 | 3 | 10 | 211 | 12 | 7 | 1 | 39 | 308 |
| Unknown | 10 | 5 | 2 | 5 | 113 | 6 | 4 | 1 | 17 | 163 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | 7 | 94 | 10 | 124 | 9 | 265 | 147 | 308 | 163 | 1127 |
| Dyslipidemias | — | 17 | 1 | 22 | 1 | 46 | 12 | 19 | 21 | 139 |
| Hyperlipidemias | — | 17 | — | 20 | — | 47 | 10 | 34 | 11 | 139 |
| Hypertension | — | 6 | 1 | 8 | — | 16 | 8 | 73 | 26 | 138 |
| Cardiovascular Diseases | — | 6 | — | 10 | 1 | 16 | 13 | 45 | 37 | 128 |
| Diabetes Mellitus | — | 2 | 1 | 3 | — | 10 | 7 | 56 | 20 | 99 |
| Atherosclerosis | — | 7 | 1 | 7 | — | 23 | 16 | 11 | 17 | 82 |
| Obesity | — | 3 | — | 5 | — | 3 | 1 | 49 | 10 | 71 |
| Hyperlipoproteinemia Type II | 1 | 2 | 1 | 4 | 2 | 24 | 4 | 9 | 10 | 57 |
| Coronary Disease | 1 | — | — | 3 | — | 20 | 8 | 7 | 15 | 54 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Organon and Co | 87 | 56 |
| 2 | AstraZeneca | 59 | 24 |
| 3 | Sanofi | 37 | 22 |
| 4 | Amgen | 35 | 24 |
| 5 | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 5 |
| 6 | Merck Sharp & Dohme LLC | 27 | 15 |
| 7 | Novartis Pharmaceuticals | 23 | 10 |
| 8 | Pfizer | 17 | 2 |
| 9 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 17 | 5 |
| 10 | Esperion Therapeutics, Inc. | 15 | 6 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Ezetimibe | 154 |
| 2 | Atorvastatin | 134 |
| 3 | Rosuvastatin Calcium | 86 |
| 4 | Simvastatin | 84 |
| 5 | alirocumab | 49 |
| 6 | evolocumab | 43 |
| 7 | 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid | 25 |
| 8 | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 25 |
| 9 | Pravastatin | 23 |
| 10 | Ezetimibe, Simvastatin Drug Combination | 22 |
Evidence
- Results reported
- 31.7%273 of 860 completed
- Published
- 15.5%133 of 860 completed
- Primary endpoint met
- 91%352 of 387 analyses
- Median months to report
- 16
Documents disclosed
Trial profile
- Median enrollment
- 126
- Median duration
- 17.4months
- Countries
- 79
- Study sites
- 11926
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 67
- Phase 1
- 41
- Phase 1/2
- 50
- Phase 2
- 95
- Phase 2/3
- 80
- Phase 3
- 414
- Phase 4
- 90
- Not applicable
- 70
- Unknown
- 810
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Cincinnati | United States | 97 |
| 2 | Jacksonville | United States | 70 |
| 3 | Indianapolis | United States | 64 |
| 4 | Chicago | United States | 63 |
| 5 | Houston | United States | 63 |
| 6 | Richmond | United States | 63 |
| 7 | Miami | United States | 55 |
| 8 | Dallas | United States | 52 |
| 9 | St Louis | United States | 52 |
| 10 | Amsterdam | Netherlands | 51 |
Terminations
- Terminated
- 61
- Withdrawn
- 20
- Suspended
- 2
- Stopped for recruitment
- 1.5%17 of 1127 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04031469 Suspended | Suspended | Administrative | 2030-12-10 |
| NCT04148339 Withdrawn | Withdrawn | Company focus shifted | 2030-07-31 |
| NCT05393882 Withdrawn | Withdrawn | Insufficient funding | 2027-12-31 |
| NCT05704439 Withdrawn | Withdrawn | not funded | 2027-01-31 |
| NCT05720156 Withdrawn | Withdrawn | Lack of Feasibility | 2026-03-31 |
| NCT05834673 Terminated | Terminated | Loss of strategic interest by the funding party. The participants' recruitment rate failed to meet the target within the pre-specified recruitment windows. | 2024-12-19 |
| NCT04314167 Terminated | Terminated | poor recruitment | 2024-03-01 |
| NCT02818283 Terminated | Terminated | lack of recruitment and funding | 2023-10-31 |
| NCT05594979 Terminated | Terminated | The recruitment period has come to an end and will not be renewed due to insufficient recruitment. | 2023-09-27 |
| NCT04277741 Withdrawn | Withdrawn | PI departure from university | 2023-06-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Hypercholesterolemia trials on ClinicalTrials.gov →